Propranolol inhibits cavernous vascular malformations by β1 adrenergic receptor antagonism in animal models

Propranolol, a pleiotropic β-adrenergic blocker, has been anecdotally reported to reduce cerebral cavernous malformations (CCMs) in humans. However, propranolol has not been rigorously evaluated in animal models, nor has its mechanism of action in CCM been defined. We report that propranolol or its...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Invest
Main Authors: Li, Wenqing, Shenkar, Robert, Detter, Mathew R., Moore, Thomas, Benavides, Christian, Lightle, Rhonda, Girard, Romuald, Hobson, Nicholas, Cao, Ying, Li, Yan, Griffin, Erin, Gallione, Carol, Zabramski, Joseph M., Ginsberg, Mark H., Marchuk, Douglas A., Awad, Issam A.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Clinical Investigation 2021
Assuntos:
Concise Communication
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7843213/
https://ncbi.nlm.nih.gov/pubmed/33301422
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI144893
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados